Intraperitoneal administration of nesfatin‑1 stimulates glucagon‑like peptide‑1 secretion in fasted mice.

ABSTRACT: Increasing endogenous secretion of glucagon‑like peptide (GLP)‑1 is considered a promising therapeutic approach for type 2 diabetes because decreased GLP‑1 plasma concentrations have been observed in patients with this condition. Nesfatin‑1, which is a central and peripheral anorexigenic peptide, has been reported to release GLP‑1 from enteroendocrine STC‑1 cells, although whether nesfatin‑1 stimulates GLP‑1 secretion in vivo remains to be elucidated. Previous studies have indicated that nesfatin‑1 has glucose‑lowering and insulinotropic effects in mice and rats; however, the in vivo mechanism remains unclear. The present study aimed to investigate whether peripheral administration of nesfatin‑1 increased blood concentrations of GLP‑1 and insulin in food‑deprived mice. Nesfat

SUBMITTER: Tagawa N 

PROVIDER: S-EPMC9685253 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature